Presence of protein important clue to tumour regression in neuroblastoma

Karolinska Institutet's picture
Printer-friendly versionPrinter-friendly version

Thu, Jun 22, 2017 13:40 CET

The presence of the protein KIF1Bβ can play a central role for the outcome of a neuroblastoma diagnosis. A high percentage of KIF1Bβ means a greater chance of the tumour spontaneously regressing and disappearing. These are the results of a study by Karolinska Institutet (KI) and the Ludwig Institute for Cancer Research Ltd. The study is published in the scientific journal Genes and Development.

Neuroblastoma is the third most common form of childhood cancer and causes almost 15 per cent of all cancer-related deaths in children. This high mortality fully reflects both the aggressive nature of the disease and that it often gives rise to secondary tumours (metastases). Paradoxically enough, neuroblastoma also has the highest spontaneous regression frequency of all tumoural diseases.

In the present study, the researchers showed that absence of KIF1Bβ contributes to normal neuroblasts not maturing into nerve cells and to a more immature neuroblastoma with a poorer prognosis.

“Our study shows that unimpaired maturing of neuroblasts is a basic prerequisite for spontaneous regression of neuroblastoma. What is behind this regression is unknown, but our study is an important piece in the jigsaw for understanding the mechanisms that cause this phenomenon. Understanding this process in greater detail can provide clues for the development of new therapies. For example, it would be interesting to increase levels of KIF1Bβ activity to see if this facilitates, or even induces, tumour regression,” comments Susanne Schlisio, researcher at KI’s Department of Microbiology, Tumor and Cell Biology and at Ludwig Institute for Cancer Research Ltd.

High gene expression of the NGF receptor TRKA correlates well with good prognoses and with spontaneous regression of the tumour. Conversely, low levels of Trka, partnered with loss of the 1p36 chromosome locus and amplification of the MYCN oncogene, are associated with poor prognoses.

We have previously shown that the kinesin protein KIF1Bβ, which is present on chromosome 1p36, is a candidate tumour suppressor and that a low expression is correlated with lower survival of neuroblastoma patients,” says Schlisio.

The research is being financed with funding from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Paradifference Foundation and the Gösta Fraenckel Foundation for Medical Research.

Publication

“Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ mediated transport of TRKA” , Stuart M. Fell, Shuijie M. Li, Karin Wallis, Anna Kock, Olga Surova, Vilma Rraklli, Carolin S. Höfig, Wenyu Li, Jens Mittag, Marie Arsenian Henriksson, Rajappa S. Kenchappa, Johan Holmberg, Per Kogner and Susanne Schlisio, Genes and Development, online 21 June, 2017/297077

For more information about the research, please contact
Susanne Schlisio, researcher
The Department of Microbiology, Tumor and Cell Biology
Karolinska Insitutet
The Ludwig Institute for Cancer Research Ltd.
Tel: + 46 (0)8 524 87117

Contact the Press Office and download photo:   ki.se/pressroom

Karolinska Institutet is one of the world’s leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.

Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

1 + 0 =

To prevent automated spam submissions leave this field empty.